Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes
Alexander E. Sherman,Gabriela Motyckova,K. Rebecca Fega,Daniel J. DeAngelo,Gregory A. Abel,David P. Steensma,Martha Wadleigh,Richard Stone,Jane A. Driver,Jane A. Driver,Jane A. Driver +10 more
Reads0
Chats0
TLDR
The results support the use of geriatric assessment to better predict prognosis in older patients with AML, even among those with excellent functional status.About:
This article is published in Leukemia Research.The article was published on 2013-09-01 and is currently open access. It has received 88 citations till now. The article focuses on the topics: Comorbidity.read more
Citations
More filters
Journal ArticleDOI
Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology
Margaret R. O'Donnell,Martin S. Tallman,Camille N. Abboud,Jessica K. Altman,Frederick R. Appelbaum,Daniel A. Arber,Vijaya Raj Bhatt,Dale L. Bixby,William Blum,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Steven D. Gore,Aric C. Hall,Patricia Kropf,Jeffrey E. Lancet,Lori J. Maness,Guido Marcucci,Michael Gary Martin,Joseph O. Moore,Rebecca L. Olin,Deniz Peker,Daniel A. Pollyea,Keith W. Pratz,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Eunice S. Wang,Matthew J. Wieduwilt,Kristina M. Gregory,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger and older adult patients.
Journal ArticleDOI
How I treat the older patient with acute myeloid leukemia
TL;DR: The dilemmas in tailoring treatment selection in this category of patients with AML are the central theme in this discussion.
Journal ArticleDOI
Frailty and the management of hematologic malignancies.
Gregory A. Abel,Heidi D. Klepin +1 more
TL;DR: In this paper, the authors defined frailty and its relevance for patients with hematologic malignancy and proposed elements of a new research agenda for geriatric hematology: the exchange of age limits for rigorous frailty screening, development of disease-specific measures, and inclusion of functional and patient-reported outcomes alongside survival.
Journal ArticleDOI
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults
TL;DR: Clinical trials accounting for the heterogeneity of tumor biology and aging are needed to define standard-of-care treatments for both disease groups and should include outcomes addressing quality of life, maintenance of independence, and use of health care services to assist in patient-centered decision making.
Journal ArticleDOI
Myelodysplastic syndromes current treatment algorithm 2018.
TL;DR: Individual risk stratification using tools such as the revised International Prognostic Scoring System (IPSS-R) is important in managing patients—including selecting candidates for allogeneic hematopoietic stem cell transplantation (ASCT), the only potentially curative therapy for MDS.
References
More filters
Journal ArticleDOI
Gait speed and survival in older adults.
Stephanie A. Studenski,Subashan Perera,Kushang V. Patel,Caterina Rosano,Kimberly A. Faulkner,Marco Inzitari,Jennifer S. Brach,Julie Chandler,Peggy M. Cawthon,Elizabeth Connor,Michael C. Nevitt,Marjolein Visser,Stephen B. Kritchevsky,Stefania Badinelli,Tamara B. Harris,Anne B. Newman,Jane A. Cauley,Luigi Ferrucci,Jack M. Guralnik +18 more
TL;DR: In this pooled analysis of individual data from 9 selected cohorts, gait speed was associated with survival in older adults and predicted survival was as accurate as predicted based on age, sex, use of mobility aids, and self-reported function.
Journal ArticleDOI
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan Kenneth Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield +18 more
TL;DR: An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
Journal ArticleDOI
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson,John M. Bennett,Kenneth J. Kopecky,Thomas Büchner,Cheryl L. Willman,Elihu H. Estey,Charles A. Schiffer,Hartmut Doehner,Martin S. Tallman,T. Andrew Lister,Francesco Lo-Coco,Roel Willemze,Andrea Biondi,Wolfgang Hiddemann,Richard A. Larson,Bob Löwenberg,Miguel A. Sanz,David R. Head,Ryuzo Ohno,Clara D. Bloomfield +19 more
TL;DR: An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials as mentioned in this paper.
Journal ArticleDOI
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Mohamed L. Sorror,Michael B. Maris,Michael B. Maris,Rainer Storb,Rainer Storb,Frédéric Baron,Brenda M. Sandmaier,Brenda M. Sandmaier,David G. Maloney,David G. Maloney,Barry E. Storer,Barry E. Storer +11 more
TL;DR: The new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival and will be useful for clinical trials and patient counseling before HCT.
Journal ArticleDOI
Age and acute myeloid leukemia
Frederick R. Appelbaum,Holly Gundacker,David R. Head,Marilyn L. Slovak,Cheryl L. Willman,John E. Godwin,Jeanne E. Anderson,Stephen H. Petersdorf +7 more
TL;DR: The combination of a poor performance status and advanced age identified a group of patients with a very high likelihood of dying within 30 days of initiating induction therapy, arguing for age-specific assessments when evaluating therapies for AML.
Related Papers (5)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Survival for older patients with acute myeloid leukemia: a population-based study.
Betul Oran,Daniel J. Weisdorf +1 more